PD-L1 expression on peripheral CD8+ T cells may serve as a biomarker of tumor response, which can be easily assessed in the clinical situation, but requires further exploration for its prognostic/predictive power in studies testing this novel triple combination. The gene discussed is CD274; the disease is neoplasm.